Associated Papers
Clinicopathological and molecular characterization of KRAS wild-type pancreatic ductal adenocarcinomas reveals precursor lesions with oncogenic mutations and fusions in RAS pathway genes.
Toriyama K et al.
The Journal of Pathology, 2025
40317966 (PubMed )
Supplement: PATH-266-337-s002.zip › path6432-sup-0004-TableS4.xlsx › PDAC-093
Novel insights into tumorigenesis revealed by molecular analysis of Lynch syndrome cases with multiple colorectal tumors.
Olkinuora A et al.
Frontiers in Oncology, 2024
38725616 (PubMed )
Supplement: Table_2.xlsx › Table_S2
EYA2 suppresses the progression of hepatocellular carcinoma via SOCS3-mediated blockade of JAK/STAT signaling.
Liu ZK et al.
Molecular Cancer, 2021
34044846 (PubMed )
Supplement: 12943_2021_1377_MOESM2_ESM.zip › Additional_file_2-Table_S3.xlsx › non-silent_mutations_and_indel
Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML.
Lindblad O et al.
Oncogene, 2016
26999641 (PubMed )
Supplement: onc201641x2.pdf
Single-cell mRNA sequencing identifies subclonal heterogeneity in anti-cancer drug responses of lung adenocarcinoma cells.
Kim KT et al.
Genome Biology, 2015
26084335 (PubMed )
Supplement: 13059_2015_692_MOESM2_ESM.xls › Xeno_pooled
Genomic differences between pure ductal carcinoma in situ and synchronous ductal carcinoma in situ with invasive breast cancer.
Kim SY et al.
Oncotarget, 2015
25831047 (PubMed )
Supplement: oncotarget-06-7597-s002.xlsx › Table_S1
Single-cell sequencing analysis characterizes common and cell-lineage-specific mutations in a muscle-invasive bladder cancer.
Li Y et al.
Gigascience, 2012
23587365 (PubMed )
Supplement: 2047-217X-1-12-S5.xls › Table_S2B
Select a paper to view details